Latest news with #GLP-1-based
France 24
3 days ago
- Health
- France 24
The big business behind weight-loss drugs: Global market to hit $150 billion by 2035
12:43 Issued on: 12:43 min They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive big pharma's revenue for years to come. But they come with a hefty price tag, while some 50 to 70 percent of people taking GLP-1s suffer side effects. Charles Pellegrin asks Frederic Bizard, a health economist and professor at ESCP Business School, who has the most to gain from this pharma revolution.
Yahoo
24-06-2025
- Health
- Yahoo
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
Biomea Fusion (BMEA) announced the presentation of new preclinical and clinical data for icovamenib, the company's investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association June 20-23, 2025 in Chicago. Biomea presented three abstracts: one oral presentation and two posters, all highlighting icovamenib's therapeutic potential across key dimensions of T2D pathophysiology, including its impact on beta cell restoration, and synergy with glucagon-like peptide-1 receptor agonists to promote metabolic health and selective fat loss with complete lean mass preservation. Presentation Summaries: Title: Combination Therapy of Icovamenib and Semaglutide Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model: Summary: In a Zucker Diabetic Fatty rat model of T2D, treatment of icovamenib in combination with low-dose semaglutide delivered superior metabolic benefits compared to low-dose semaglutide alone: 60% lower fasting blood glucose and 50% lower glucose OGTT AUC; Greater HbA1c decline; greater than1% by Day 28 and greater than2% by Day 39; Greater improvement in insulin sensitivity with a 75% lower HOMA-IR; 2-fold increase in C-peptide to glucose ratio indicating enhanced beta cell function; Superior appetite suppression with a 10% greater body weight reduction than low-dose semaglutide alone; The observed body weight loss was primarily due to fat mass reduction with complete preservation of lean mass; These findings support the potential of icovamenib to enhance the therapeutic effects of GLP-1-based therapies. The combination may allow lower doses of GLP-1-based therapies to achieve glycemic and weight loss targets and improve tolerability of these agents, offering a compelling rationale for clinical evaluation of icovamenib-based combination regimens. Title: Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model: Summary: This preclinical study evaluated icovamenib's direct effects on ex vivo human myotube cultures and the effects of icovamenib in combination with low-dose semaglutide in an in vivo rodent model of diabetes: In ex vivo cultures of iPSC-derived 3D-engineered human myotubes, icovamenib treatment promoted healthy myotube morphology; Separately, icovamenib diminished drug-induced atrophy by activin A or dexamethasone, suggesting muscle health supporting effects of icovamenib; In a ZDF rat study, combination treatment with icovamenib and low-dose semaglutide induced greater body weight reduction with complete preservation of lean mass, outperforming low-dose semaglutide; These early findings support icovamenib's unique potential when combined with GLP-1-based therapies to enhance body weight reduction and protect lean mass, a highly desirable feature for any long-term diabetes or obesity therapy. Title: COVALENT-111: 26-Week Efficacy and Safety after 8 and 12 Weeks of Daily Oral Icovamenib in Patients with Poorly Controlled Type 2 Diabetes: Summary: 26-week follow-up results from the ongoing Phase II COVALENT-111 trial highlight the potential of short-course oral icovamenib treatment to deliver durable glycemic control and improved beta cell function, in patients with poorly controlled T2D, particularly in the insulin-deficient subgroup. Key findings include: Icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide in severe insulin-deficient participants at Week 26, three months after the last dose; Over half of the C-peptide improvement occurred during the off-treatment period, indicating a durable effect on endogenous insulin production; Short-course dosing led to sustained HbA1c reductions through Week 26 across the broader study population; Changes in HbA1c correlated significantly with changes in C-peptide, supporting the proposed mechanism of action to restore beta-cell function; In patients inadequately controlled on baseline GLP-1 RA therapy, icovamenib added to the GLP-1 RA led up to an additional 1.0% mean HbA1c reduction. Icovamenib was well tolerated across all dosing arms, with a low incidence of treatment-emergent adverse events, no clinically significant elevations in ALT or AST, and no study drug discontinuations or discontinuations from the trial due to adverse events Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
11-06-2025
- Health
- Business Upturn
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
San Francisco, June 10, 2025 (GLOBE NEWSWIRE) — PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States. Accessible at the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes. 'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.' Expanded Features for 2025 The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment with integrated results for precision treatment Transparent Pricing with no insurance required The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery. Addressing a Growing National Health Concern According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers. Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy. About PlushCare PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare. For more information, visit Media Contact:PlushCare Media Relations Email: [email protected] Website: Address: 345 California Street, Suite 600, San Francisco, CA 94105, United States
Yahoo
10-06-2025
- Health
- Yahoo
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss
Virtual platform now offers licensed physician care for testosterone therapy, GLP-1 weight loss support, and men's wellness programs across all 50 U.S. states San Diego, June 10, 2025 (GLOBE NEWSWIRE) -- a U.S.-based telehealth provider specializing in men's hormonal optimization and metabolic wellness, has officially expanded its clinical care services nationwide. This expansion supports a growing number of men seeking personalized healthcare solutions for low testosterone, weight challenges, and performance-related health issues—all from the convenience of their own home. Through its secure platform, connects patients to licensed U.S. physicians who evaluate medical history, review lab work, and prescribe clinically appropriate treatment programs. The company's services now reach patients in all 50 states, including those in remote or underserved areas where access to specialized care may be limited. 'Our mission is to make medically supervised hormone therapy and weight loss care more accessible for men everywhere,' said a spokesperson for 'This nationwide expansion reflects our commitment to safe, evidence-based telemedicine that empowers patients to take charge of their long-term health.' virtual platform is designed for ease of use, featuring: Fast, secure medical intake and scheduling Lab partnerships for at-home or local diagnostic testing Ongoing provider monitoring and patient support HIPAA-compliant communication channels Nationwide medication delivery where legally permitted All care is provided by board-certified physicians and licensed healthcare professionals who follow strict clinical guidelines. Treatment options may include testosterone replacement therapy (TRT), GLP-1-based metabolic weight programs, and supportive interventions for men's health, always following a personalized and physician-reviewed protocol. With recent updates to its website and mobile user interface, has also improved patient onboarding, reduced consultation wait times, and expanded clinical support availability. About is a telehealth company focused on optimizing men's health through medical evaluation, diagnostic testing, and customized treatment plans. The company specializes in testosterone therapy, weight management, and performance-focused wellness protocols—delivered entirely online through licensed U.S. providers. By combining technology with medical oversight, empowers men to pursue health goals with professional guidance and national reach. Contact: AM – 8:00 PM EDT Monday – Friday9:00 AM – 5:00 PM EDT Saturday – Sunday16776 Bernardo Center Dr. Suite 203, San Diego, CA 92128https:// SOURCE: Disclaimer This press release is for informational purposes only. provides healthcare services under licensed clinical supervision in compliance with state and federal regulations. No part of this release should be interpreted as medical advice or a substitute for an in-person doctor consultation. Treatment eligibility, outcomes, and availability may vary based on individual patient circumstances and state-specific regulations. CONTACT: 1-888-299-5088 support@ 8:00 AM – 8:00 PM EDT Monday – Friday 9:00 AM – 5:00 PM EDT Saturday – SundayError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@
